EST
CARM

EA Series Trust’s Carisma Therapeutics CARM Stock Holding History

EA Series Trust’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$355K Buy
+40,434
New +$220K 0.01% 911

Other funds holding CARM

TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $297M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

EA Series Trust's CARM Position: Q2 2023 in Review

EA Series Trust opened a new position in Carisma Therapeutics (CARM) in Q2 2023: 40,434 shares worth $355K. The stake represents 0.01% of the portfolio and ranks #911 among its holdings.

53 funds tracked by Wall St. Rank hold CARM as of Q2 2023.

  • EA Series Trust held 40,434 shares of Carisma Therapeutics worth $355K as of Q2 2023.
  • Carisma Therapeutics was a new EA Series Trust position in Q2 2023.
  • Carisma Therapeutics made up 0.01% of EA Series Trust's portfolio in Q2 2023, its #911 holding.
  • 53 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.